Home - Products - Angiogenesis - VEGFR - UNC0064-12 hydrochloride (1430089-64-7(free base))

UNC0064-12 hydrochloride (1430089-64-7(free base))

CAS No. ——

UNC0064-12 hydrochloride (1430089-64-7(free base))( —— )

Catalog No. M22768 CAS No. ——

UNC0064-12 hydrochloride is an inhibitor of VEGFR2 extracted from patent WO2013055780A1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 357 In Stock
10MG 597 In Stock
25MG 882 In Stock
50MG 1350 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    UNC0064-12 hydrochloride (1430089-64-7(free base))
  • Note
    Research use only, not for human use.
  • Brief Description
    UNC0064-12 hydrochloride is an inhibitor of VEGFR2 extracted from patent WO2013055780A1.
  • Description
    UNC0064-12 hydrochloride is an inhibitor of VEGFR2 extracted from patent WO2013055780A1.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    VEGFR
  • Recptor
    VEGFR2
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    ——
  • Formula Weight
    400.91
  • Molecular Formula
    C19H25ClN8
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    Cl.NCCCNc1ccc(Nc2nccc(Nc3cc([nH]n3)C3CC3)n2)cc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. MULTIPLEXED KINASE INHIBITOR BEADS AND USES THEREOF. Patent Application WO/2013/055780 Kind Code: A1
molnova catalog
related products
  • GSK269962A

    GSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.

  • Cabozantinib hydroch...

    Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM).

  • Fargesin

    Fargesin as a potential β1AR antagonist through cAMP/PKA pathway could protect against myocardial ischemia/reperfusion injury in rats.